Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
1.2Native cysteine attachment
What ifWhat if R5 uses a native surface cysteine as the attachment site?
Claim language“cysteine residues introduced by mutation”
A naturally occurring free thiol on R5 reacts with a maleimide on the functional moiety to form a covalent thioether. A surface site away from the binding interface keeps the attachment point clear of the target contact residues.
1.4Attachment through lysine nitrogen
What ifWhat if the functional moiety attaches through the side-chain nitrogen of a surface lysine?
Claim language“sulfur atom(s) of the cysteine residue(s)”
An activated ester on the functional moiety reacts with the lysine side-chain amine to form an amide. The resulting bond anchors the functional moiety to R5 while the release segment controls removal of the mask.
1.5Partial shielding of binding
What ifWhat if a tethered polymer reduces the rate of target binding while leaving the binding site accessible?
Claim language“prevents R5 from binding”
A short polyethylene glycol chain sweeps across part of the binding surface and reduces the frequency of productive target encounters. Targets still bind through exposed portions of the interface, and polymer release increases the association rate.
1.6Light triggered mask release
What ifWhat if near-ultraviolet light cleaves R2 to release the mask?
Claim language“activated by one or more proteolytic enzymes”
An ortho-nitrobenzyl ester in R2 absorbs light near 365 nanometers and fragments. The cut separates the masking segment from R5 and exposes the binding surface.
1.7Spacer retained after cleavage
What ifWhat if R3 stays attached to R5 after R2 is cleaved?
Claim language“automatically shedding after R2 is cleaved”
Cleavage of R2 releases the bulky masking group. R3 is a short alkyl spacer joined through a stable amide, and its attachment point lies outside the target contact surface so that R5 can bind after mask release.
Section 2 · machine-generated
Variations
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
Other field of use
Acid activated dye capture in textiles
A cysteine-engineered dye-binding protein carries a steric mask on a sulfur-linked tether with an acid-cleavable spacer. The protein is dispersed in a textile coating with its dye-binding pocket masked. An acidic finishing rinse releases the mask and leaves a short tether stub on the protein, exposing the pocket to dye in the rinse.
Component substitution
Light activated release of a steric mask
An ortho-nitrobenzyl carbonate replaces the pH-sensitive release bond between a polyethylene glycol mask and a short spacer anchored to an engineered cysteine on a fluorescent hapten-binding protein. The mask sits next to the binding pocket, and the spacer projects away from the pocket. Illumination at 365 nanometers cleaves the carbonate, releasing the mask and leaving the sulfur-linked spacer on the protein.
Disulfide release of a protein mask
A reducible disulfide replaces the acid-sensitive bond between a polyethylene glycol mask and the spacer on a cysteine-engineered dye-binding protein. A stable thioether anchors the spacer to the protein, with the disulfide positioned farther from the protein surface. A cell-free assay adds tris(2-carboxyethyl)phosphine to split the disulfide and release the mask. The protein retains a spacer with a terminal thiol, and a dye-binding assay measures recovery after buffer exchange.
Parameter or scale variation
Mask size series for binding assays
Three versions of a cysteine-engineered hapten-binding protein carry linear polyethylene glycol masks with nominal molecular masses of 2, 5, or 10 kilodaltons. Each version uses one mask per protein molecule, with the same attachment site, acid-cleavable linker, and sulfur-linked spacer. A bench assay measures fluorescent hapten binding before the acid pulse and again after neutralization. The paired measurements show how mask size affects initial blocking and binding recovery.
Combination with existing systems
Inline activation in a microfluidic cartridge
A microfluidic cartridge has reservoirs for masked dye-binding protein, acidic buffer, neutralizing buffer, and fluorescent dye. The first junction combines the protein and acidic buffer, and a serpentine channel provides residence time for mask cleavage. A second junction returns the stream to the protein's binding pH before a third junction adds dye. A downstream flow cell measures the fluorescence change as the exposed protein binds the dye.
Automated or data-driven variant
Automated measurement of binding recovery
A liquid handler distributes a cysteine-linked, acid-cleavable conjugate of a hapten-binding protein across a microplate. Software schedules acid pulses of different durations, adds neutralizing buffer at each endpoint, and dispenses a fluorescent hapten tracer. A plate reader measures fluorescence polarization, which rises as the tracer binds the exposed protein. Software normalizes each reading against masked and unmasked controls and fits a binding recovery curve against pulse duration.
Specific version of a part
Release regenerates the free thiol
A disulfide directly joins the masking appendage to the protein cysteine. Reduction separates the two sulfur atoms, releases the appendage, and restores access to the binding surface.
Tethered peptide occupies binding pocket
A short peptide recognition motif serves as R1 and reversibly occupies the ligand-binding pocket on R5. The tether keeps the peptide near the pocket until cleavage releases it to diffuse into the surrounding solution.
Acid hydrolyzes a hydrazone
R2 contains a hydrazone formed by condensation of a hydrazide with an aldehyde. Acidic conditions accelerate hydrazone hydrolysis and separate the masking segment from the protein-linked segment.
Aminobenzyl spacer fragments after cleavage
R3 is a para-aminobenzyl carbamate spacer. Cleavage of R2 exposes the aromatic amine, which initiates spacer fragmentation and releases the group attached through the carbamate.
Short spacer clears binding surface
R4 is a short polyethylene glycol spacer anchored by a thioether to a cysteine on the side of R5 opposite the binding surface. After mask release, the retained spacer projects into solvent and leaves the target contact residues accessible.
Section 3 · quoted from USPTO records
Other work
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Partially reduced c5D7 was alkylated with 2.4 molar of maleimidocaproyl-monomethyl dolastatin 10/mAb-cysteine thiol.
A · US 2016/0015830 A1 · ¶ 399
In another embodiment of the disclosure, masked anti-EGFR antibody fragments are generated by cloning domain III of the soluble EGFR (sEGFRdIII) N-terminal to a cleavable linker followed by single chain variable fragment (scFv) versions of the anti-EGFR antibodies Matuzumab (mAb425 or 425) and Cetuximab (mAbC225 or C225) (FIGS. 9A and 17).
B · US 2016/0144042 A1 · ¶ 62
1.2wherein, R5 represents a biomolecule with one or more cysteine residues introduced by mutation;
1.3wherein, cys represents the cysteine residue(s) contained in R5;
The concentration of mAb-cysteine thiols produced was determined by titrating with DTNB (or 5,5′-dithiobis-(2-nitrobenzoic acid)).
A · US 2016/0015830 A1 · ¶ 399
1.4wherein, S represents sulfur atom(s) of the cysteine residue(s);
In some embodiments, the targeting moiety comprising a sulfhydryl group or thiol group bonds to a linker via the sulfur atom in the sulfhydryl group.
A · US 2016/0015830 A1 · ¶ 189
1.5wherein, R1 is a group that prevents R5 from binding to its antigen, ligand or receptor;
In some embodiments, two mAbs may form a heterodimer to produce a cross-masked mAb complex, comprising a first masked mAb comprising (1) a first masked antibody or fragment thereof having an antigen recognition site attached to a first masking epitope via a flexible linker, and (2) a second masked mAb comprising a second antibody or fragment thereof having an antigen recognition site attached to a second masking epitope via a flexible linker.
B · US 2016/0144042 A1 · ¶ 6
1.6wherein, R2 is absent, or R2 is a cleavable linker arm capable of being activated by one or more proteolytic enzymes or a chemical bond capable of being acidically activated in a pathologic microenvironment;
Enzyme-labile linkers take an alternative approach-the differential activities of proteases inside and outside of the cells-to achieve control of the drug release.
A · US 2016/0015830 A1 · ¶ 6
The flexible linker may be cleaved by a protease specific to a target tissue allowing the cross-masked mAb heterodimer complex to dissociate at the target tissue.
B · US 2016/0144042 A1 · ¶ 6
1.7wherein, R3 is absent, or R3 is a linker arm capable of automatically shedding after R2 is cleaved or a chemical bond capable of being acidically activated in a pathologic microenvironment; with the proviso that when R2 is absent, R3 is the chemical bond capable of being acidically activated in a pathologic microenvironment; and
The compounds of the present disclosure comprise a drug moiety, a targeting moiety capable of targeting a selected cell population, and a linker which contains an acyl unit, an optional spacer unit for providing distance between the drug moiety and the targeting moiety, a peptide linker which can be cleavable under appropriate conditions, a hydrophilic self-immolative linker, and an optional second self-immolative spacer or cyclization self-elimination linker.
A · US 2016/0015830 A1 · abstract
1.8wherein, R4 is a group covalently linked to R5 via the sulfur atom(s) of the cysteine residue(s) contained in R5 that recovers, maintains or promotes the binding capacity of R5 to its antigen, ligand or receptor after the moiety R1-R2-R3 is cleaved.
The antibodies described herein may further include analogs and derivatives that are either modified, i.e., by the covalent attachment of any type of molecule as long as such covalent attachment permits the antibody to retain its antigen binding immunospecificity.
A · US 2016/0015830 A1 · ¶ 208
An empty cell means only that no passage was reproduced there.
Statements in these documents
ADCs take advantage of characteristics of both components and significantly expand the therapeutic index of cytotoxic molecules by minimizing systemic exposure and associated toxicity while at the same time maximizing delivery of the cytotoxic agents to the target lesion, thus increasing treatment efficacy.
A · US 2016/0015830 A1 · ¶ 3
There is a need for linkers for ADCs which can provide serum stability as well as increased solubility, allowing efficient conjugation and intracellular delivery of hydrophobic drugs.
A · US 2016/0015830 A1 · ¶ 8
It would therefore be desired to develop antibodies and methods for their delivery to tumor cells that minimize effects to non-diseased tissues.
B · US 2016/0144042 A1 · ¶ 4
In one embodiment, a “prodrug” antibody design is described that ameliorates such side effects by occluding (directly or sterically), or “masking” antibody complement determining regions until they reach diseased tissues containing disease-associated proteinases.
B · US 2016/0144042 A1 · ¶ 5
Cite aspatent.fyi, US 2026/0355340 A1, claim 1, first published 2026-11-19T10:32:39-05:00, https://patent.fyi/US20260355340/, SHA-256 7e86df51032fdda0db7ddd0015d2fef5a6acc7214b5ade34f5fc896222e74aac